MicrobioSeq's Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics solutions for drug development.

The bacterial communities on the human body surface and in the body are becoming an important source of personalized medicine. The microbial community helps to improve diagnosis, detect and treat diseases early, and reduce the risk of diseases. The use of next-generation sequencing technology to identify microbial communities (including all microbes and all their genetic elements that exist on our body surfaces and bodies) allows us to now incorporate this important human disease factor into new disease prevention and treatment strategies.

Certain types of microorganisms can synthesize biologically active molecules and use them as therapeutics. More pharmaceutical companies have realized these values and turned their clinical development efforts to microbial therapies. The potential of microbial therapy is evident in probiotics and live bacteria preventive vaccines and the recent use of fecal microbiota transplantation to improve human health or cure certain diseases. In addition, microorganisms can be designed as living therapies to perform specific functions in the human body. Benefits may include preventing infections, eliminating tumors, and treating metabolic disorders. The engineered life system is considered the next generation therapy. Producing therapeutics derived from the microbes has several advantages over traditional systems: decreased production costs, side effects, and dosage requirements.

“The microbiome has progressively become an attractive target for potential therapeutics. However, one of the biggest difficulties is to determine cause-effect relationships and to design microbial therapeutics for these conditions. We are dedicated to offering a full list of microbial genomics services to accelerate the development of microbial therapeutics, including microbial whole genome sequencing, 16S/18S/ITS sequencing, metagenomics, metatranscriptomics, microbial epigenomics, as well as microbial ID and AMR profiling.” Said the Chief Scientist of CD Genomics.

What are the main research directions of CD Genomics’s Microbial Therapeutics Solutions?

1. Reveal the relationship between microorganisms and human diseases.
2. Develop engineered microorganisms for the treatment of certain human diseases.
3. Microbiome-based therapies to change the microbial composition of the human body, such as fecal microbiota transplantation.

If you are interested in CD Genomics’s Microbial Therapeutics Solutions, more information can be reached at its’ website.

About MicrobioSeq Divison of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, which is a genomics service company with a good reputation for providing reliable microbial sampling products, microbial testing services, microbial genomics services, and integrated bioinformatics services.

Contact Details

Dianna Gellar

Marketing Manager

contact@cd-genomics.com